BF Biosciences brings GLP-1 manufacturing to Pakistan

BF Biosciences Ltd has begun local manufacturing of tirzepatide, bringing one of the world’s most sought-after metabolic drugs into production on Pakistani soil. In a material disclosure to the Pakistan Stock Exchange, the company said it has launched Zeptide (tirzepatide) in an easy-to-use pre-filled syringe, produced at its new European-specification pre-filled syringes facility. The company added that developing Zeptide was included in the utilisation plan for its initial public offering (IPO) proceeds, signalling that funds raised from public investors are now translating into tangible capacity and product roll-out.

Tirzepatide – an injectable therapy that acts as a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors – is approved by the United States Food and Drug Administration (FDA) for treating type-2 diabetes and obesity. The formulation is being released in patient-friendly, pre-filled syringes, a format the company says reduces dosing errors. Independent testing of Zeptide’s quality and potency has been conducted at leading mass spectrometry facilities in the US and at a national university in Pakistan, according to the filing.